Literature DB >> 24345005

Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.

Marshall A Mazepa1, Jay S Raval, Stephan Moll, Alice Ma, Yara A Park.   

Abstract

Entities:  

Keywords:  bortezomib; thrombotic haemolytic anaemias; thrombotic thrombocytopenic purpura

Mesh：

Substances：

Year:  2013        PMID： 24345005     DOI： 10.1111/bjh.12696

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

2.  Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.

Authors:  Sumita Ratnasingam; Patricia A Walker; Huy Tran; Zane S Kaplan; James D McFadyen; Huyen Tran; Tse-Chieh Teh; Shaun Fleming; John V Catalano; Sanjeev D Chunilal; Anna Johnston; Stephen S Opat; Jake Shortt
Journal:  Blood Adv       Date:  2016-11-22

3.  Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.

Authors:  Joan D Beckman; Marian A Rollins-Raval; Jay S Raval; Yara A Park; Marshall Mazepa; Alice Ma
Journal:  Am J Ther       Date:  2018 Mar/Apr       Impact factor: 2.688

4.  Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.

Authors:  Manu R Pandey; Pankit Vachhani; Evelena P Ontiveros
Journal:  Case Rep Hematol       Date:  2017-03-06

Review 5.  Novel Therapies to Address Unmet Needs in ITP.

Authors:  María Eva Mingot-Castellano; José María Bastida; Gonzalo Caballero-Navarro; Laura Entrena Ureña; Tomás José González-López; José Ramón González-Porras; Nora Butta; Mariana Canaro; Reyes Jiménez-Bárcenas; María Del Carmen Gómez Del Castillo Solano; Blanca Sánchez-González; Cristina Pascual-Izquierdo
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-23

Review 6.  Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

Authors:  Yue Lv; Huiping Shi; Hong Liu; Lu Zhou
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

7.  mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.

Authors:  Susan Liu-Chen; Brendan Connolly; Lei Cheng; Romesh R Subramanian; Zhaozhong Han
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

8.  Novel therapies in thrombotic thrombocytopenic purpura.

Authors:  Camila Masias; Spero R Cataland
Journal:  Res Pract Thromb Haemost       Date:  2017-12-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.